BioGraph 55 key facts
- Developer of novel B-cell therapies and drugs designed to address significant unmet clinical needs of autoimmunity.
- BioGraph 55’s last known valuation is $25.0M.
- It has raised $20.1M; the latest was Later Stage VC ($11.8M) in Jun 2024.
- Notable investors include University of California, Pfizer Ventures, Red Tree Venture Capital, Panacea Venture, Los Angeles — 6 tracked in total.
- Status: Privately Held (backing).
- ·Watch BioGraph 55: the Monday email on marks, rounds and moves
BioGraph 55 funding rounds
No funding rounds for BioGraph 55 are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
BioGraph 55 valuation
BioGraph 55's last known valuation is $25 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
BioGraph 55 investors
6 investors are on record for BioGraph 55, including University of California, Pfizer Ventures, Red Tree Venture Capital and Panacea Venture.
About BioGraph 55
Developer of novel B-cell therapies and drugs designed to address significant unmet clinical needs of autoimmunity. The company offers discovering and developing bispecific antibodies for immuno-oncology and another for autoimmunity that utilizes a reverse translational approach and identifies potential cellular targets within diseased tissues and validates mechanisms, enabling healthcare professionals to capture clinically relevant content from the tumor microenvironment.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2014
- Employees
- 4
- Website
- biograph55.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
BioGraph 55’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.